Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDLN-Sparing RT + Immunotherapy + Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06676449Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2024
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fudan University. Primary endpoints: Progression-Free Survival for patients with TDLN V15 <= 50% at 2 years and Progression-Free Survival for all patients at 2 years. Started Nov 2024; status: recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06676449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676449.